Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Techniclone (TCLN) -- Ignore unavailable to you. Want to Upgrade?

To: shero who wrote (3074)	5/18/1999 3:55:00 PM
From: Tarken Winn	Read Replies (2) \| Respond to of 3702

shero, I was referring to the ASCO abstract that was posted by GregSL via Yahoo. Message 9559483 I don't really care much about the press releases. Yes it would be nice to have the stock a little further away from the $1 delisting/financing boundary, but so long as the products are working as well as they seem to be and continue progressing through the trials, I am happy. Eventually the success will be reflected in the stock price. Once Techniclone is earning the money we expect, everyone will be able to look at their EPS and determine a 'fair' price for the stock - no predicting the market size or understanding of the science necessary. At $4 EPS (profit of about $300 mil.) do you think the stock would still be a dollar? Sometime between now and $4 EPS the stock must go up. To me it doesn't matter when as I am not planning on selling before. As long as they continue to obtain financing for the trials without too much further dilution and the products are successful I will be happy. However, I do agree that the press release was weak. The key point of the results to me was in the abstract [if what I am quoting IS actually from the abstract], but not in the press release. The press release could simply have read "Cotara - Median survival and time to progression have not yet been reached. 11 of 12 patients are alive. Longest survivor is at 8 months with a pontine glioblastoma." That is the information I wanted to see. Tarken